Intervention not reported
Disability: modified Rankin Scale (mRS) A measure of disability, with 6 categories: 0 (no symptoms), 1 (no significant disability), 2 (slight disability), 3 (moderate disability), 4 (moderately severe disability), 5 (severe disability), 6 (dead); ... · adults with stroke
1 finding from 1 review
Any pain‐related outcome (moderate pain improvement) · adults with neuropathic pain
It is very uncertain whether morphine changes any pain‐related outcome (moderate pain improvement) compared with placebo (very low certainty).
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with fibromyalgia
It is very uncertain whether NSAID changes moderate pain relief: at least 30% reduction in pain, or PGIC much… compared with placebo (very low certainty).
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
1 finding from 1 review
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
1 finding from 1 review
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
It is very uncertain whether granulocyte-colony stimulating factor (G-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · women at high risk of OHSS
It is very uncertain whether human albumin changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · women at high risk of OHSS
It is very uncertain whether HES changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · women at high risk of OHSS
Mannitol may leads to lower moderate or severe OHSS compared with placebo / no treatment (low certainty).
1 finding from 1 review
Moderate or severe OHSS · patients with final oocyte maturation triggering in IVF and ICSI cycles
RhCG showed no clear difference in OHSS per woman ‐ moderate to severe OHSS compared with uhCG (low certainty).
1 finding from 1 review
Incidence of moderate OHSS · patients with final oocyte maturation triggering in IVF and ICSI cycles
It is very uncertain whether rhLH changes OHSS per woman ‐ Moderate OHSS compared with uhCG (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: a. mild to moderate hypoglycaemia (episodes per participant)
1 finding from 1 review
Intervention not reported
Adverse outcomes ‐ corneal haze score at 12 months (grade 1.0 ‐ more prominent haze that does not interfere with visibility of fine iris details; grade 2.0 ‐ mild obscuration of iris details; grade 3.0 ‐ moderate obscuration of iris and lens; and ... · adult participants (≥ 18 years) with myopia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Adverse outcomes ‐ glare and halo scores at 3 months (grade 0 ‐ none; grade 1 ‐ very low; grade 2 ‐ low; grade 3 ‐ moderate; grade 4 ‐ high; and grade 5 ‐ very high) · adult participants (≥ 18 years) with myopia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Moderate benefit: at least 30% reduction in pain, or PGIC much or very much improved · Adults with chronic neuropathic pain
1 finding from 1 review
At least 30% reduction in pain · adults with fibromyalgia
1 finding from 1 review